Pharma

Press Release

TeleChem’s Founder & VP Todd Martinsky explains TeleChem’s keys to success

Sunnyvale, CA, January 22, 2003 – On January 22nd, the drug discovery journal PharmaGenomics identified TeleChem International, Inc. as one of only two privately-held biotechnology companies in the United States to shirk a slow economy. The PharmaGenomics article (Vol. 3, number 1) recognized that TeleChem’s continued success in rather tepid economic times “scored major points for the economy’s underdogs.”

Company founder and Executive Vice President Todd Martinsky explained TeleChem’s success in the article. “We have the advantage of a really important application – gene expression. Mapping the human genome was important, but microarrays provide functional information, and that is what researchers really are after. I think were are leading a new project – “The Human Genome Function Project” – and that project starts both with DNA and protein microarrays.”

The PharmaGenomics article further explains TeleChem’s corporate history and how the company showed 492% revenue increase over the 5-year period spanning fiscal years 1997 to 2001.

“We were the first company to create microarray products as consumables and to empower researchers to perform microarray experiments. We are planning to do the same for clinical screening and diagnostics through our diagnostic division, NGS-ArrayIt,” Martinsky explained.

About TeleChem International, Inc.
TeleChem has diversified business activities organized into three corporate divisions: Life Sciences, Chemicals, and Diagnostics. The Life Sciences ArrayIt® Division provides a complete line of products and services for the microarray industry, a high-tech sector that uses tiny glass “chips” to explore the human genome. Microarray technology is speeding disease analysis, drug discovery, and crop plant development. The microarray products are sold under the ArrayIt® brand name, and include key patents (e.g. US 6,101,946) that protect the company’s core microarray manufacturing technology used in more than 10,000 corporate and university laboratories worldwide. The Chemicals Division provides import and export services and government contract work in the area of industrial chemicals including raw materials for plastics, water-soluble fertilizers, and cleaning compounds. The Chemicals Division enjoys expanding sales and profits, and provides financial support for research and development. The Diagnostics Division NGS-ArrayIt, Inc. has key patent filings in the areas of genotyping and medical diagnostics, and provides its tools and technologies to public health laboratories and other agencies involved in human disease analysis. NGS-ArrayIt plans to launch a new line of disease tests for sickle cell anemia, cystic fibrosis, hereditary hearing loss and other treatable diseases in the near future.

Media Contact
Paul Haje
Director of Public Relations
408-744-1331
Email paul@ArrayIt®.com